vs
Side-by-side financial comparison of Vertex Pharmaceuticals (VRTX) and Ventas (VTR). Click either name above to swap in a different company.
Vertex Pharmaceuticals is the larger business by last-quarter revenue ($3.0B vs $1.7B, roughly 1.8× Ventas). Vertex Pharmaceuticals runs the higher net margin — 34.5% vs 3.6%, a 31.0% gap on every dollar of revenue. On growth, Ventas posted the faster year-over-year revenue change (22.0% vs 7.8%). Over the past eight quarters, Ventas's revenue compounded faster (17.5% CAGR vs 6.3%).
Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.
Ventas is a leading real estate investment trust specializing in healthcare-related real estate assets. Its portfolio includes senior housing, medical offices, life science research facilities and rehabilitation centers, operating mainly across North America and the UK, serving healthcare operators and life science groups.
VRTX vs VTR — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $3.0B | $1.7B |
| Net Profit | $1.0B | $59.0M |
| Gross Margin | 86.8% | — |
| Operating Margin | 38.1% | — |
| Net Margin | 34.5% | 3.6% |
| Revenue YoY | 7.8% | 22.0% |
| Net Profit YoY | 59.6% | 19.0% |
| EPS (diluted) | $4.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $3.0B | $1.7B | ||
| Q4 25 | $3.2B | $1.6B | ||
| Q3 25 | $3.1B | $1.5B | ||
| Q2 25 | $3.0B | $1.4B | ||
| Q1 25 | $2.8B | $1.4B | ||
| Q4 24 | $2.9B | $1.3B | ||
| Q3 24 | $2.8B | $1.2B | ||
| Q2 24 | $2.6B | $1.2B |
| Q1 26 | $1.0B | $59.0M | ||
| Q4 25 | $1.2B | $73.0M | ||
| Q3 25 | $1.1B | $68.7M | ||
| Q2 25 | $1.0B | $71.5M | ||
| Q1 25 | $646.3M | $48.4M | ||
| Q4 24 | $913.0M | $58.7M | ||
| Q3 24 | $1.0B | $21.0M | ||
| Q2 24 | $-3.6B | $21.2M |
| Q1 26 | 86.8% | — | ||
| Q4 25 | 85.4% | — | ||
| Q3 25 | 86.5% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 86.9% | — | ||
| Q4 24 | 85.5% | — | ||
| Q3 24 | 85.8% | — | ||
| Q2 24 | 85.9% | — |
| Q1 26 | 38.1% | — | ||
| Q4 25 | 37.8% | 4.9% | ||
| Q3 25 | 38.6% | 3.0% | ||
| Q2 25 | 38.8% | 3.0% | ||
| Q1 25 | 22.7% | 3.0% | ||
| Q4 24 | 35.2% | -0.0% | ||
| Q3 24 | 40.3% | 1.5% | ||
| Q2 24 | -132.9% | -1.6% |
| Q1 26 | 34.5% | 3.6% | ||
| Q4 25 | 37.3% | 4.7% | ||
| Q3 25 | 35.2% | 4.6% | ||
| Q2 25 | 34.8% | 5.0% | ||
| Q1 25 | 23.3% | 3.6% | ||
| Q4 24 | 31.4% | 4.6% | ||
| Q3 24 | 37.7% | 1.7% | ||
| Q2 24 | -135.8% | 1.8% |
| Q1 26 | $4.02 | — | ||
| Q4 25 | $4.64 | $0.15 | ||
| Q3 25 | $4.20 | $0.14 | ||
| Q2 25 | $3.99 | $0.15 | ||
| Q1 25 | $2.49 | $0.10 | ||
| Q4 24 | $3.62 | $0.13 | ||
| Q3 24 | $4.01 | $0.05 | ||
| Q2 24 | $-13.92 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $183.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $19.4B | $13.2B |
| Total Assets | $26.5B | $27.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $183.6M | ||
| Q4 25 | $6.6B | $741.1M | ||
| Q3 25 | $6.3B | $188.6M | ||
| Q2 25 | $6.4B | $614.2M | ||
| Q1 25 | $6.2B | $182.3M | ||
| Q4 24 | $6.1B | $897.9M | ||
| Q3 24 | $6.5B | $1.1B | ||
| Q2 24 | $5.8B | $557.1M |
| Q1 26 | — | — | ||
| Q4 25 | — | $13.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $13.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $19.4B | $13.2B | ||
| Q4 25 | $18.7B | $12.5B | ||
| Q3 25 | $17.3B | $12.4B | ||
| Q2 25 | $17.2B | $11.5B | ||
| Q1 25 | $16.5B | $11.5B | ||
| Q4 24 | $16.4B | $10.8B | ||
| Q3 24 | $15.6B | $9.8B | ||
| Q2 24 | $14.8B | $9.6B |
| Q1 26 | $26.5B | $27.7B | ||
| Q4 25 | $25.6B | $27.6B | ||
| Q3 25 | $24.9B | $26.9B | ||
| Q2 25 | $24.0B | $26.5B | ||
| Q1 25 | $22.9B | $26.0B | ||
| Q4 24 | $22.5B | $26.2B | ||
| Q3 24 | $22.2B | $25.3B | ||
| Q2 24 | $20.1B | $24.5B |
| Q1 26 | — | — | ||
| Q4 25 | — | 1.04× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.26× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VRTX
| TRIKAFTA/KAFTRIO | $2.4B | 79% |
| ALYFTREK | $424.4M | 14% |
| Other | $135.9M | 5% |
| CASGEVY | $42.9M | 1% |
| Vertex recorded | $29.0M | 1% |
VTR
| Resident fees and services | $1.3B | 78% |
| Outpatient medical and research portfolio | $230.1M | 14% |
| Triple-net leased properties | $123.1M | 7% |
| Third-party capital management revenues | $4.4M | 0% |
